Drug Index

Fusidic acid

 
print
Synonym :

Sodium Fusidate

Mechanism :

Fusidic acid is a bacteriostatic antibiotic that is often used topically in creams and eyedrops but may also be given systemically as tablets or injections.
Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.


Indication :

• Staphylococcal skin infections.


Contraindications :

Hypersensitivity


Dosing :

Topical: Apply to affected area 2-3 times daily.


Adverse Effect :

Hypersensitivity reactions such as burning, mild irritation, redness or swelling to cream. Loss of appetite, abdominal or stomach pain, increase in bowel movements, nausea, loose stools.


Interaction :

Amprenavir: The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid.
Atorvastatin: Increased risk of myopathy/rhabdomyolysis.
Fosamprenavir: The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid.
Indinavir: Indinavir may increase the effect and toxicity of fusidic acid.
Nelfinavir: The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid.
Penicillin V: Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid.
Ritonavir: The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.
Saquinavir: The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid.
Simvastatin: Increased risk of myopathy/rhabdomyolysis.
Ticarcillin: Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid.
Tipranavir: Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxicity of both agents.



Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDNot dialysed. Dose as in normal renal function

Hepatic Dose :

No dosage adjustments are recommended.
05/20/2020 22:08:26 Fusidic acid
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0